The biggest weight-loss myths are that obesity is simply a willpower problem, that metabolism is permanently "broken," that one macronutrient (carbs, sugar, insulin) uniquely causes obesity, that GLP-1 medications are cheating or a quick fix, and that regaining weight means personal failure. Body weight is regulated by biology, behaviour and environment together — and the evidence, not the marketing, should decide.
Section accent: family --teal. This is the flagship searchable myth database — the DEBUNK layer of the DiaEndo editorial arc.
HOW TO USE THIS DATABASE
This is the single place where we collect the claims patients bring us — from clinics, headlines, group chats and supplement ads — and grade each one honestly. Some are outright false. Many are half-true: a real biological kernel stretched into a slogan. We tell you which is which.
Every entry uses the same compact format: the MYTH in plain words · a one- or two-sentence SHORT ANSWER · WHAT THE EVIDENCE SHOWS · WHAT REMAINS UNCERTAIN (named out loud) · a one-line BOTTOM LINE · and an EVIDENCE grade.
The grades (letter is canonical; colour is the visual tag): - A · Established 🟢 — strong evidence and/or guideline-backed. - B · Promising / Moderate 🟡 — good but with real uncertainty. - C · Limited / Conflicting 🟠 — small, inconsistent, or of uncertain relevance. - D · Experimental 🔴 — not established for routine care. - E · Unsupported ⚫ — no convincing evidence of benefit (or the claim is simply false).
A grade describes the strength of the evidence about the claim, not our approval of it. "This supplement works" graded E ⚫ means the evidence says it doesn't. "Obesity is a chronic disease" graded A 🟢 means the evidence strongly supports it.
Category filter. The database is organised into 17 categories — use the filter chips to jump to one, or search a keyword. On the live site each chip maps to ?topic= (e.g. /myths?topic=glp1), and the "All questions →" links on every chapter feed into the matching filter.
Two rules we never break: we never give a weight-loss figure without its drug, dose, trial, population and duration; and we never confuse a plausible mechanism with proof in humans. Where a specific number isn't independently verified, we say so qualitatively or mark it [verify].
1. WEIGHT & METABOLISM
“Weight is just calories in versus calories out — it's simple arithmetic.”
Short answer: The energy-balance equation is true but incomplete; the body actively adjusts both sides.
What the evidence shows: Hunger, satiety, spontaneous activity and resting expenditure are regulated by hormones and the brain, so "calories out" changes when "calories in" changes — which is why sustained loss is hard.
What remains uncertain: The precise size of each adaptive response varies between people.
Bottom line: Thermodynamics holds; the controller behind the numbers is biology, not willpower.
Evidence: 🟢 A · Established · Why Weight Is So Hard to Lose →
“Obesity is a choice / a simple failure of willpower.”
Short answer: Obesity is a chronic, relapsing disease of body-weight regulation, not a character flaw.
What the evidence shows: Genetics, the hormonal environment, medications, sleep, stress and the food environment powerfully shape weight; heritability is roughly 40–70%.
What remains uncertain: How much any individual's weight is modifiable, and by which lever.
Bottom line: Behaviour matters, but calling obesity "a choice" is scientifically wrong.
Evidence: 🟢 A · Established · Obesity as a Chronic Disease →
“My metabolism is permanently broken from years of dieting.”
Short answer: Metabolism adapts to weight loss, but "permanently broken" overstates it.
What the evidence shows: Losing weight lowers energy expenditure somewhat more than size alone predicts (adaptive thermogenesis), and appetite hormones shift toward hunger — but resting metabolism tracks largely with body and muscle mass, not damage.
What remains uncertain: How long adaptive thermogenesis persists and how much varies widely.
Bottom line: Your metabolism is defending a set point, not destroyed.
Evidence: 🟡 B · Promising · Weight Regain & Maintenance →
“Some people have a naturally fast metabolism and can eat anything.”
Short answer: Metabolic rate varies between people, but far less than the visible differences in what people eat.
What the evidence shows: Most between-person variation in resting metabolism is explained by body size and lean mass; true "fast metabolizers" of similar size differ modestly, and thin people often move and eat differently than assumed.
What remains uncertain: The contribution of non-exercise activity (fidgeting, spontaneous movement) between individuals.
Bottom line: Metabolism differs, but not enough to explain large weight gaps by itself.
Evidence: 🟡 B · Promising
“Starvation mode means eating too little makes you gain weight.”
Short answer: Severe restriction slows metabolism and drives hunger, but it does not make you gain fat while in an energy deficit.
What the evidence shows: Under-eating lowers expenditure and increases appetite (adaptive responses), which stalls loss and promotes later regain — it doesn't create fat from nothing.
What remains uncertain: How aggressively to restrict before adaptation outweighs the benefit.
Bottom line: Extreme dieting backfires through regain, not by magically adding weight.
Evidence: 🟡 B · Promising
“Metabolism inevitably crashes at 40 and that's why people gain weight.”
Short answer: Total energy expenditure is remarkably stable from about 20 to 60; midlife weight gain is mostly behaviour, muscle loss and environment.
What the evidence shows: Large expenditure studies show adjusted metabolic rate holds steady through midlife and declines only later; midlife gain reflects falling activity, muscle loss and lifestyle, not a metabolic cliff.
What remains uncertain: How much hormonal shifts (e.g. menopause) alter fat distribution versus total expenditure.
Bottom line: Blame the environment and muscle loss, not a 40th-birthday metabolic collapse. → Aging & Weight (below)
Evidence: 🟡 B · Promising
“You can be obese but perfectly metabolically healthy, so weight doesn't matter.”
Short answer: "Metabolically healthy obesity" exists but is often a temporary stage, not a stable safe zone.
What the evidence shows: Some people with obesity have normal glucose, lipids and blood pressure — but many progress to metabolic disease over time, and higher adiposity still raises some risks.
What remains uncertain: Who stays metabolically healthy long-term and why.
Bottom line: Health, not the scale, is the outcome — but "healthy now" is not "healthy forever."
Evidence: 🟡 B · Promising · What Is Obesity? →
“BMI is useless / BMI is the whole story.”
Short answer: BMI is a useful population screen but a crude individual measure — the truth is in between.
What the evidence shows: BMI misclassifies very muscular people and can miss high visceral fat in others; waist circumference and body composition add important information.
What remains uncertain: The best single practical adiposity measure for individuals.
Bottom line: Use BMI as a starting flag, then look at where the fat is and what it's doing.
Evidence: 🟢 A · Established · BMI, Body Fat & Body Composition →
“Everyone has a 'set point' weight that can never change.”
Short answer: The body defends a weight range biologically, but that range can shift up (and, with treatment, down).
What the evidence shows: Physiology resists loss (hunger up, expenditure down), which explains regain; but medications, surgery and sustained lifestyle change can lower the defended level.
What remains uncertain: Whether a lowered set point becomes permanent after stopping treatment.
Bottom line: The set point is defended, not fixed forever.
Evidence: 🟡 B · Promising
“Eating late at night makes calories count more.”
Short answer: Total intake matters far more than the clock, though late eating can nudge behaviour and metabolism slightly.
What the evidence shows: In controlled studies meal timing has small effects on appetite and energy use; most "late eating causes weight gain" findings reflect people simply eating more overall at night.
What remains uncertain: Modest circadian effects on metabolism are real but small in magnitude.
Bottom line: When you eat matters much less than how much.
Evidence: 🟠 C · Limited
2. NUTRITION
“Carbohydrates cause obesity.”
Short answer: No single macronutrient causes obesity; excess energy and highly processed foods do most of the work.
What the evidence shows: Whole-carbohydrate populations can be lean; controlled diets matched for calories show no unique fattening effect of carbohydrate independent of intake.
What remains uncertain: How much refined-carb foods drive overeating via palatability and glycaemic swings.
Bottom line: Refined, hyper-palatable foods are the problem — not carbohydrates as a class.
Evidence: 🟢 A · Established · Nutrition →
“Sugar is uniquely toxic and the single cause of the obesity epidemic.”
Short answer: Excess added sugar is genuinely harmful, but it is not the sole cause of obesity.
What the evidence shows: Sugar-sweetened drinks are linked to weight gain and metabolic disease; still, obesity rose through a whole food environment, not one ingredient.
What remains uncertain: The independent metabolic harm of sugar versus its role as easy excess calories.
Bottom line: Cut sugary drinks — but don't expect one villain to explain everything.
Evidence: 🟡 B · Promising
“Keto is metabolically superior for fat loss.”
Short answer: Keto works for some people, but head-to-head it isn't magically superior once calories and protein match.
What the evidence shows: Low-carb diets produce fast early loss (largely water) and can help appetite and glucose; long-term weight loss is similar to other diets of equal adherence.
What remains uncertain: Whether specific subgroups (e.g. marked insulin resistance) do better on lower-carb patterns.
Bottom line: The best diet is the healthy one you can sustain — keto is an option, not a requirement.
Evidence: 🟡 B · Promising
“Breakfast is the most important meal — skipping it makes you fat.”
Short answer: Eating breakfast has no unique metabolic magic; it helps only if it helps you eat well overall.
What the evidence shows: Randomised trials show adding or skipping breakfast has little effect on weight by itself; benefits depend on total intake and food quality.
What remains uncertain: Individual differences in appetite control across the day.
Bottom line: Eat breakfast if it helps you; skipping it is not a metabolic mistake.
Evidence: 🟡 B · Promising
“Fasting resets or 'boosts' your metabolism.”
Short answer: Intermittent fasting is a valid way to cut calories, but it doesn't reset or speed metabolism.
What the evidence shows: Time-restricted eating and alternate-day fasting produce weight loss comparable to standard calorie restriction, mainly by reducing intake; metabolic-rate benefits beyond weight loss are small or unproven.
What remains uncertain: Possible modest circadian and insulin-sensitivity benefits of earlier eating windows.
Bottom line: Fasting is a tool for eating less, not a metabolic reset.
Evidence: 🟡 B · Promising
“You must eat every 2–3 hours to 'stoke the metabolic fire.'”
Short answer: Meal frequency has little effect on metabolic rate; total intake is what counts.
What the evidence shows: Trials comparing many small meals with fewer larger ones show no meaningful metabolic or weight advantage at equal calories.
What remains uncertain: Frequency effects on appetite and adherence vary by person.
Bottom line: Eat on a schedule that controls your hunger — frequency itself doesn't burn fat.
Evidence: 🟡 B · Promising
“Eating fat makes you fat.”
Short answer: Dietary fat isn't uniquely fattening; excess total energy is.
What the evidence shows: Higher-fat Mediterranean-style diets support weight and cardiometabolic health; low-fat dogma didn't stop obesity rising.
What remains uncertain: How fat type interacts with overall diet pattern for long-term outcomes.
Bottom line: Quality and quantity of the whole diet matter more than fat grams.
Evidence: 🟢 A · Established
“'Negative-calorie' foods like celery burn more than they contain.”
Short answer: No common food has negative net calories.
What the evidence shows: The energy to digest food (thermic effect) is a small fraction of its content; celery is low-calorie and filling, but not calorie-negative.
What remains uncertain: Nothing meaningful — the physiology is settled.
Bottom line: Low-calorie, high-volume foods help; "negative-calorie" foods are a myth.
Evidence: ⚫ E · Unsupported
“Detoxes and cleanses flush out fat and toxins.”
Short answer: Your liver and kidneys already detoxify; cleanses don't remove fat.
What the evidence shows: No credible evidence that detox products improve health or cause lasting weight loss; early "loss" is water and gut contents.
What remains uncertain: Nothing that supports the marketing claims.
Bottom line: Save your money; support your liver and kidneys with basics, not cleanses.
Evidence: ⚫ E · Unsupported · Natural & Alternative Approaches →
“Gluten-free means healthier and helps you lose weight.”
Short answer: Unless you have celiac disease or gluten sensitivity, going gluten-free offers no weight benefit.
What the evidence shows: Gluten-free processed foods are often higher in sugar and fat; any weight loss comes from cutting processed carbs, not gluten.
What remains uncertain: Non-celiac gluten sensitivity is a real but poorly defined entity.
Bottom line: Gluten-free is essential for some, irrelevant for weight in most.
Evidence: 🟠 C · Limited
“Eating more protein is pointless for weight loss.”
Short answer: Higher protein genuinely helps — for fullness and for protecting muscle.
What the evidence shows: Adequate protein increases satiety, has a higher thermic effect, and preserves lean mass during weight loss, especially alongside resistance training.
What remains uncertain: Optimal amount for each person and goal.
Bottom line: Protein is one of the few nutrition levers with solid support.
Evidence: 🟢 A · Established · Exercise, Muscle & Body Composition →
“'Superfoods' and specific fat-burning foods melt fat.”
Short answer: No single food burns fat; overall dietary pattern is what matters.
What the evidence shows: Foods marketed as fat-burners (green tea, chili, grapefruit) have negligible effects on body fat in humans.
What remains uncertain: Tiny thermogenic effects exist but are clinically irrelevant.
Bottom line: There are healthy foods, but no fat-melting ones.
Evidence: ⚫ E · Unsupported
3. EXERCISE
“Exercise is the main way to lose weight.”
Short answer: Exercise is powerful for health but a weak lever for weight loss on its own.
What the evidence shows: Because the body compensates (more hunger, less spontaneous movement), exercise alone usually produces modest weight loss; diet drives most loss.
What remains uncertain: How much compensation varies between people.
Bottom line: Exercise for health and maintenance; rely on intake for loss.
Evidence: 🟢 A · Established · Exercise, Muscle & Body Composition →
“Exercise is useless for weight — don't bother.”
Short answer: The opposite error: exercise is one of the strongest predictors of keeping weight off and of health at any weight.
What the evidence shows: Physical activity improves cardiovascular risk, insulin sensitivity, mood and muscle, and is strongly associated with successful weight maintenance.
What remains uncertain: Optimal type and dose for maintenance in each person.
Bottom line: Poor tool for losing, excellent tool for health and for not regaining.
Evidence: 🟢 A · Established · Weight Regain & Maintenance →
“You can spot-reduce belly fat with crunches.”
Short answer: Targeted exercises build muscle under the fat but don't preferentially burn fat there.
What the evidence shows: Fat is mobilised systemically; spot-reduction trials consistently fail to show localised fat loss.
What remains uncertain: Nothing meaningful — this is well settled.
Bottom line: Train the muscle; lose fat globally through overall balance.
Evidence: ⚫ E · Unsupported
“Cardio is the only exercise that matters for weight.”
Short answer: Resistance training is at least as important, mainly for protecting muscle and metabolic health.
What the evidence shows: Strength training preserves lean mass during weight loss, improves insulin sensitivity and function; combined training is best.
What remains uncertain: Ideal cardio-to-resistance ratio for a given goal.
Bottom line: Do both — lifting protects the muscle dieting can cost you.
Evidence: 🟢 A · Established
“The 'fat-burning zone' at low intensity burns the most fat.”
Short answer: Lower intensity uses a higher proportion of fat, but higher intensity burns more total calories and fat.
What the evidence shows: Total energy expenditure, not fuel percentage, drives fat loss; both intensities work if calories are controlled.
What remains uncertain: Individual preferences and recovery shape the best choice.
Bottom line: Pick intensity you'll sustain; total energy matters more than the "zone."
Evidence: 🟡 B · Promising
“No pain, no gain — exercise must hurt to work.”
Short answer: Effective activity does not require pain; consistency beats intensity.
What the evidence shows: Moderate regular activity delivers most health benefits; pain often signals injury risk, which derails consistency.
What remains uncertain: Optimal challenge level varies by fitness and goals.
Bottom line: Sustainable effort, not suffering, produces results.
Evidence: 🟢 A · Established
“You can out-exercise a bad diet.”
Short answer: Very few people can; it's far easier to eat calories than to burn them.
What the evidence shows: Exercise energy is limited and partly compensated, so diet quality dominates weight outcomes.
What remains uncertain: A small minority with very high training volumes are exceptions.
Bottom line: You cannot reliably outrun your fork.
Evidence: 🟢 A · Established
“Muscle turns to fat when you stop training.”
Short answer: Muscle and fat are different tissues; one cannot become the other.
What the evidence shows: Stopping training shrinks muscle and, if intake stays high, adds fat — two separate changes that look like a swap.
What remains uncertain: Nothing — the biology is clear.
Bottom line: Muscle atrophies and fat accumulates; neither transforms into the other.
Evidence: ⚫ E · Unsupported
“Sweating more means you're burning more fat.”
Short answer: Sweat is temperature regulation, not a fat gauge.
What the evidence shows: Sweat loss is water weight, regained on rehydration; it doesn't measure calories or fat burned.
What remains uncertain: Nothing relevant.
Bottom line: A hot, sweaty session isn't proof of more fat loss.
Evidence: ⚫ E · Unsupported
“Exercise makes you gain weight, so it's counterproductive.”
Short answer: Early scale rises are usually muscle, water and glycogen — not fat.
What the evidence shows: New training can transiently increase water and lean mass and appetite; body composition and health still improve.
What remains uncertain: How much appetite compensation offsets loss varies.
Bottom line: Judge exercise by fitness, waist and strength — not the first-week scale.
Evidence: 🟡 B · Promising
4. GLP-1 (GENERAL)
“GLP-1 medications are cheating.”
Short answer: Treating a biological disease with a medicine that corrects biology is not cheating.
What the evidence shows: GLP-1 drugs reduce appetite and "food noise" by acting on the same appetite-regulating pathways obesity disrupts; we don't call insulin or blood-pressure pills cheating.
What remains uncertain: Nothing about the ethics; long-term individual outcomes still vary.
Bottom line: Using an evidence-based medicine for a chronic disease is treatment, not a shortcut.
Evidence: 🟢 A · Established · GLP-1 & Incretin Medications →
“GLP-1s are brand-new and untested.”
Short answer: GLP-1 receptor agonists have been used in diabetes for well over a decade.
What the evidence shows: These drugs have years of use and large outcome trials (e.g. cardiovascular benefit); the newer story is higher-dose obesity efficacy, not an untested class.
What remains uncertain: Very-long-term (decades) obesity-specific data are still accumulating.
Bottom line: A well-studied class with a newer, higher-efficacy chapter.
Evidence: 🟢 A · Established
“GLP-1s are dangerous / too good to be true.”
Short answer: They have real, mostly manageable side effects and rare serious risks — not a hidden catastrophe.
What the evidence shows: Common effects are gastrointestinal (nausea, constipation); serious events are uncommon; large trials show net health benefit including cardiovascular risk reduction.
What remains uncertain: Extremely long-term safety continues to be monitored.
Bottom line: Real risks, honestly manageable, against substantial proven benefit.
Evidence: 🟢 A · Established · GLP-1 Side Effects →
“You take GLP-1s for a few months and you're cured.”
Short answer: Obesity is chronic; stopping the drug usually leads to regain.
What the evidence shows: On withdrawal, appetite returns and much of the lost weight comes back — after semaglutide, roughly two-thirds of lost weight within about a year.
What remains uncertain: Whether some patients maintain loss with structured lifestyle support after stopping.
Bottom line: These treat a chronic condition; they're generally long-term, like other chronic-disease medicines.
Evidence: 🟢 A · Established · Weight Regain & Maintenance →
“GLP-1s destroy your muscle.”
Short answer: Weight loss of any kind reduces some lean mass; "destroys muscle" overstates it.
What the evidence shows: DXA lean-mass falls with weight loss (as expected), but this includes water and organ mass, not just muscle; protein intake and resistance training protect strength and function.
What remains uncertain: Long-term effects on strength and physical function need more data.
Bottom line: Expect some lean-mass loss; protect it with protein and lifting — it isn't muscle destruction.
Evidence: 🟡 B · Promising · GLP-1 & Muscle Loss →
“'Ozempic face' means the drug damages your skin.”
Short answer: Facial changes come from fat loss, not a skin toxicity.
What the evidence shows: Rapid weight loss reduces facial fat, which can look ageing; the same happens with any fast loss method.
What remains uncertain: How much slower loss mitigates it.
Bottom line: It's fat loss showing in the face, not skin damage.
Evidence: 🟡 B · Promising
“GLP-1s cause depression and suicidal thoughts.”
Short answer: Regulators reviewed this signal and did not find a causal link.
What the evidence shows: Analyses to date have not established that GLP-1s cause suicidal ideation; monitoring continues as standard.
What remains uncertain: Rare individual psychiatric responses can't be fully excluded, so clinical vigilance is appropriate.
Bottom line: No established causal link; report mood changes to your clinician.
Evidence: 🟡 B · Promising
“GLP-1s are only for people with diabetes.”
Short answer: They are approved for chronic weight management in people without diabetes.
What the evidence shows: Obesity trials (STEP, SURMOUNT) enrolled people without diabetes; efficacy is actually greater in those without diabetes than with it.
What remains uncertain: Nothing about the indication; access and cost vary.
Bottom line: Approved for obesity, not just diabetes.
Evidence: 🟢 A · Established
“Everyone loses the same huge amount on GLP-1s.”
Short answer: Response varies widely; trial averages are not personal predictions.
What the evidence shows: Around a third of people are strong responders while others lose little; averages (e.g. STEP 1 ~15%) hide a broad range.
What remains uncertain: We cannot yet reliably predict who will respond best.
Bottom line: Your result may be well above or below the headline average.
Evidence: 🟢 A · Established
“Compounded GLP-1s are the same as the branded drug, just cheaper.”
Short answer: Compounded versions are not FDA-approved products and carry quality and dosing risks.
What the evidence shows: Compounded products vary in purity, concentration and labelling; dosing errors and contamination have been reported.
What remains uncertain: Individual product quality is unknowable without testing.
Bottom line: Same molecule name doesn't mean same safety, quality or oversight.
Evidence: 🟠 C · Limited · Compounded GLP-1s →
“Once you start a GLP-1 you can eat whatever you want.”
Short answer: The drug reduces appetite, but nutrition still matters for muscle, nutrients and health.
What the evidence shows: Adequate protein, resistance training and food quality improve body composition and reduce side effects; the drug is a tool, not a licence.
What remains uncertain: Optimal diet composition on-treatment is still being refined.
Bottom line: GLP-1s work best alongside good nutrition, not instead of it.
Evidence: 🟡 B · Promising
5. TIRZEPATIDE
“Tirzepatide is just semaglutide with a different name.”
Short answer: It's a different molecule — a dual GLP-1/GIP agonist, not a GLP-1 alone.
What the evidence shows: Tirzepatide activates two incretin receptors; in a head-to-head trial (SURMOUNT-5) it produced greater average loss (~20.2% vs ~13.7%).
What remains uncertain: Exactly how the GIP component contributes is still debated.
Bottom line: A distinct dual agonist with, on average, greater efficacy.
Evidence: 🟢 A · Established · Tirzepatide →
“Tirzepatide is always better than semaglutide for everyone.”
Short answer: On average it produces more weight loss, but "on average" isn't "for everyone."
What the evidence shows: SURMOUNT-5 favoured tirzepatide on mean loss; individual responses, tolerability, access and cost still determine the best choice.
What remains uncertain: Who does better on which drug can't be predicted in advance.
Bottom line: Greater average effect, but the right drug is individual.
Evidence: 🟢 A · Established · Semaglutide vs Tirzepatide →
“Zepbound and Mounjaro are different drugs.”
Short answer: They are the same molecule (tirzepatide) branded for different indications.
What the evidence shows: Zepbound is approved for weight management (and obstructive sleep apnea with obesity); Mounjaro for type 2 diabetes — same active ingredient.
What remains uncertain: Nothing about the molecule; formulations/indications differ.
Bottom line: One drug, two brand names and indications.
Evidence: 🟢 A · Established
“Tirzepatide is approved to treat fatty liver disease.”
Short answer: It shows promise for MASH in trials but is not FDA-approved for it — semaglutide is.
What the evidence shows: SYNERGY-NASH showed improved MASH resolution, but tirzepatide lacks a liver indication; semaglutide 2.4 mg gained MASH F2–F3 approval (Aug 2025).
What remains uncertain: Whether tirzepatide will earn a liver indication later.
Bottom line: Promising for the liver, not yet approved for it.
Evidence: 🟡 B · Promising · GLP-1 & Fatty Liver →
“Tirzepatide has cardiovascular-outcome proof like semaglutide.”
Short answer: Its cardiovascular-outcome trials are still maturing; no SELECT-equivalent claim yet.
What the evidence shows: Tirzepatide improves many risk factors, but the definitive event-reduction trials (e.g. SURMOUNT-MMO) are ongoing.
What remains uncertain: The size of any hard-outcome benefit.
Bottom line: Strong risk-factor data; hard-outcome proof is pending.
Evidence: 🟡 B · Promising
“Tirzepatide's sleep-apnea approval is just marketing.”
Short answer: It's based on a real trial showing reduced apnea events.
What the evidence shows: SURMOUNT-OSA reduced the apnea-hypopnea index, leading to FDA approval for moderate-to-severe OSA in adults with obesity (Dec 2024).
What remains uncertain: Long-term effects on OSA outcomes and CPAP dependence.
Bottom line: A genuine, trial-backed indication for OSA with obesity.
Evidence: 🟢 A · Established
“GIP should make weight worse, so tirzepatide shouldn't work.”
Short answer: GIP biology in obesity is genuinely unsettled, yet the dual agonist clearly works.
What the evidence shows: Whether GIP agonism or functional antagonism helps is debated, but clinical results are strong regardless of the mechanism argument.
What remains uncertain: The precise role of GIP co-agonism.
Bottom line: The mechanism is debated; the efficacy is not.
Evidence: 🟢 A · Established
“Tirzepatide doesn't interact with any other medications.”
Short answer: It has a labelled interaction with oral contraceptives.
What the evidence shows: Delayed gastric emptying can affect oral contraceptive absorption; the label advises a backup or non-oral method for about four weeks when starting or increasing the dose.
What remains uncertain: Real-world failure rates are hard to quantify.
Bottom line: Use backup contraception around dose changes if relevant.
Evidence: 🟢 A · Established
“You can keep the weight off easily after stopping tirzepatide.”
Short answer: Like other GLP-1s, stopping typically leads to regain.
What the evidence shows: SURMOUNT-4 showed weight regain after withdrawal versus continued loss on the drug.
What remains uncertain: Whether structured maintenance can limit regain for some.
Bottom line: Plan maintenance before stopping — regain is the default.
Evidence: 🟢 A · Established
6. SEMAGLUTIDE
“Ozempic and Wegovy are different drugs.”
Short answer: Same molecule (semaglutide), branded for diabetes (Ozempic) and weight (Wegovy).
What the evidence shows: Wegovy uses the higher weight-management dose; Ozempic is the diabetes brand — identical active ingredient.
What remains uncertain: Nothing about the molecule.
Bottom line: One drug, two brands and doses.
Evidence: 🟢 A · Established · Semaglutide →
“Semaglutide guarantees ~15% weight loss.”
Short answer: ~15% is the STEP 1 average, not a guarantee; individual results vary widely.
What the evidence shows: STEP 1 (68 weeks, no diabetes) showed ~15% mean loss versus ~2.4% placebo; about a third lost ≥20%, others much less.
What remains uncertain: Who lands where on that spectrum.
Bottom line: ~15% is an average benchmark, not your promised result.
Evidence: 🟢 A · Established
“It works just as well if you have diabetes.”
Short answer: Weight loss tends to be somewhat less in people with type 2 diabetes.
What the evidence shows: STEP 2 (diabetes) showed ~9.6% mean loss — meaningful but less than in people without diabetes.
What remains uncertain: The mechanisms behind the blunted response.
Bottom line: Effective in diabetes, but expect somewhat less weight loss.
Evidence: 🟢 A · Established
“Semaglutide is only about weight and blood sugar.”
Short answer: It reduces cardiovascular events in high-risk patients, independent of diabetes.
What the evidence shows: SELECT showed roughly a 20% reduction in major cardiovascular events (HR ~0.80) over about three years in people with established cardiovascular disease and overweight/obesity without diabetes.
What remains uncertain: How much benefit comes from weight loss versus direct drug effects.
Bottom line: A proven cardiovascular benefit, not just a weight drug.
Evidence: 🟢 A · Established · Obesity & Cardiovascular Health →
“Semaglutide can't help the liver.”
Short answer: It's now FDA-approved for noncirrhotic MASH with F2–F3 fibrosis.
What the evidence shows: The ESSENCE program showed improved MASH resolution (and, less so, fibrosis), supporting accelerated approval (Aug 2025).
What remains uncertain: Long-term fibrosis and outcome benefits are still being confirmed.
Bottom line: A genuine, approved role in metabolic liver disease.
Evidence: 🟢 A · Established · MASH Medications →
“There's no oral version — it's injections only.”
Short answer: Oral semaglutide exists, including a new higher-dose oral for obesity.
What the evidence shows: Oral semaglutide (Rybelsus) has been used in diabetes; an oral 25 mg dose was approved for chronic weight management (Dec 2025) — the first oral GLP-1 for obesity.
What remains uncertain: How oral efficacy compares long-term with injectables in practice.
Bottom line: Oral options exist, including a new obesity approval.
Evidence: 🟢 A · Established
“If I stop semaglutide, the weight stays off.”
Short answer: Stopping usually causes substantial regain.
What the evidence shows: A STEP 1 extension found roughly two-thirds of lost weight returned within about a year of stopping, with cardiometabolic gains reversing.
What remains uncertain: Whether intensive maintenance changes this for some patients.
Bottom line: Discontinuation generally means regain — plan ahead.
Evidence: 🟢 A · Established · Weight Regain & Maintenance →
“Semaglutide is safe to keep taking if I get pregnant.”
Short answer: It should be stopped before pregnancy given its long half-life.
What the evidence shows: Guidance advises stopping roughly two months before conception; it is not recommended in pregnancy.
What remains uncertain: Human pregnancy safety data are limited.
Bottom line: Plan to stop well before trying to conceive.
Evidence: 🟢 A · Established
“Semaglutide causes thyroid cancer in people.”
Short answer: The boxed warning comes from rodent data; a human causal link isn't established.
What the evidence shows: Rodents developed medullary thyroid tumours; human evidence has not confirmed this risk, but it's contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
What remains uncertain: Very-long-term human thyroid data are still limited.
Bottom line: A precautionary contraindication, not a demonstrated human cancer cause.
Evidence: 🟡 B · Promising
“You should stop semaglutide before surgery — or it doesn't matter.”
Short answer: It's generally held before surgery because it delays gastric emptying.
What the evidence shows: Delayed emptying raises aspiration concerns under anaesthesia, so perioperative holding is advised.
What remains uncertain: The ideal hold duration is still being standardised.
Bottom line: Tell your surgical and anaesthesia team; expect to hold it.
Evidence: 🟡 B · Promising
7. SUPPLEMENTS
“Berberine is 'nature's Ozempic.'”
Short answer: Berberine affects glucose and lipids modestly but is not a GLP-1 and doesn't act like one.
What the evidence shows: It can nudge blood glucose and cholesterol; evidence for meaningful weight loss is limited and inconsistent.
What remains uncertain: Long-term effects and drug-interaction risk (it inhibits CYP enzymes).
Bottom line: A real metabolic agent, not a weight-loss drug or an Ozempic substitute.
Evidence: 🟠 C · Limited · Weight-Loss Supplements →
“Green tea extract burns fat.”
Short answer: Any effect is tiny and mostly from caffeine.
What the evidence shows: Trials show very small, inconsistent weight effects; concentrated extracts carry a rare but real liver-injury risk.
What remains uncertain: Nothing that would make it clinically useful.
Bottom line: Fine as tea; useless as a fat-burner and occasionally risky concentrated.
Evidence: 🟠 C · Limited
“Apple cider vinegar melts fat.”
Short answer: At best it slightly blunts glucose; it doesn't melt fat.
What the evidence shows: Small studies show minor effects on satiety or glucose; weight effects are negligible.
What remains uncertain: Modest appetite effects in some people.
Bottom line: Not a weight-loss treatment.
Evidence: 🟠 C · Limited
“Garcinia cambogia / HCA causes weight loss.”
Short answer: Rigorous trials show little to no meaningful effect.
What the evidence shows: Weight effects are small and inconsistent; rare liver toxicity has been reported.
What remains uncertain: Nothing supporting the marketing.
Bottom line: Ineffective and not risk-free.
Evidence: ⚫ E · Unsupported
“Chromium picolinate controls appetite and weight.”
Short answer: Effects on weight are negligible.
What the evidence shows: Meta-analyses show trivial weight change; glucose effects are minor.
What remains uncertain: Nothing clinically relevant.
Bottom line: Not worth taking for weight.
Evidence: ⚫ E · Unsupported
“'Fat burner' thermogenics safely torch calories.”
Short answer: Effects are small and side effects can be significant.
What the evidence shows: Stimulant blends slightly raise metabolism short-term; tolerance develops, and cardiovascular and anxiety effects occur.
What remains uncertain: Product contents are often unlabelled or contaminated.
Bottom line: Small benefit, real risk, poor regulation.
Evidence: 🟠 C · Limited
“Raspberry ketones work because they worked on cells/mice.”
Short answer: Cell and animal effects have not translated to humans.
What the evidence shows: No credible human trials show weight loss.
What remains uncertain: Nothing supporting use.
Bottom line: A marketing story, not a human result.
Evidence: ⚫ E · Unsupported
“Fiber supplements are a gimmick.”
Short answer: Fiber is one of the few supplements with a genuine, if modest, role.
What the evidence shows: Soluble fibers (psyllium) improve fullness, glucose and cholesterol; whole-food fiber is best.
What remains uncertain: Magnitude of weight benefit is small.
Bottom line: Real but modest — prefer fiber from food.
Evidence: 🟡 B · Promising
“Protein powder is unnecessary if you're dieting.”
Short answer: Adequate protein is valuable; powder is just a convenient source.
What the evidence shows: Higher protein supports satiety and preserves lean mass during loss; the source (food or powder) matters less than the total.
What remains uncertain: Optimal intake per person.
Bottom line: Hit your protein target — powder helps if food falls short.
Evidence: 🟡 B · Promising
“Creatine makes you fat / is only for bodybuilders.”
Short answer: Creatine adds a little water weight in muscle, not fat, and supports strength.
What the evidence shows: It improves resistance-training performance and lean mass; the early scale rise is intramuscular water.
What remains uncertain: Long-term role specifically during weight loss.
Bottom line: Useful for preserving strength; the "weight" is water, not fat.
Evidence: 🟡 B · Promising
“'GLP-1 booster' supplements raise your own GLP-1 enough to matter.”
Short answer: No supplement meaningfully replicates GLP-1 medication effects.
What the evidence shows: Some foods/fibers modestly stimulate gut hormones, but nowhere near pharmacologic levels; "natural GLP-1" products lack real weight-loss evidence.
What remains uncertain: Small physiologic effects exist but are clinically trivial.
Bottom line: Not a substitute for a GLP-1 drug.
Evidence: ⚫ E · Unsupported
8. HORMONES
“My thyroid explains my obesity.”
Short answer: Thyroid disease can contribute to weight but rarely explains most of it.
What the evidence shows: Untreated hypothyroidism causes modest weight gain (largely fluid); once treated, it seldom accounts for significant obesity.
What remains uncertain: Subtle effects of thyroid status on metabolism at the margins.
Bottom line: Check the thyroid, but don't expect it to explain the whole picture.
Evidence: 🟢 A · Established · Obesity & Hormones →
“Cortisol is the hidden cause of my weight gain.”
Short answer: True cortisol-driven obesity (Cushing's) is rare; everyday "stress cortisol" is a minor player.
What the evidence shows: Chronic stress influences appetite and fat distribution modestly; genuine cortisol excess is uncommon and has other tell-tale signs.
What remains uncertain: The size of stress-related effects on weight in individuals.
Bottom line: Manage stress for health, but cortisol rarely explains obesity.
Evidence: 🟡 B · Promising
“Insulin is the master hormone that causes obesity (the carbohydrate-insulin model).”
Short answer: Insulin matters, but the evidence doesn't support it as the singular cause.
What the evidence shows: Controlled feeding studies don't confirm the strong version of the carbohydrate-insulin model; energy balance still governs fat mass.
What remains uncertain: Insulin's role in appetite and fat storage in specific subgroups.
Bottom line: Insulin is a contributor, not the master switch.
Evidence: 🟡 B · Promising
“Leptin supplements will fix my appetite.”
Short answer: Most people with obesity are leptin-resistant, not leptin-deficient, so leptin doesn't help.
What the evidence shows: Leptin therapy works only in rare genuine leptin deficiency; in common obesity, high leptin already fails to suppress appetite.
What remains uncertain: Whether leptin-sensitizing strategies could help.
Bottom line: Leptin isn't a treatment for common obesity.
Evidence: ⚫ E · Unsupported
“Balancing my hormones will make the weight fall off.”
Short answer: "Hormone balancing" is a marketing phrase, not a defined medical treatment.
What the evidence shows: Specific disorders (thyroid, PCOS, hypogonadism) warrant targeted treatment; generic "hormone reset" programs lack evidence.
What remains uncertain: Which subtle endocrine factors matter for a given person.
Bottom line: Treat diagnosed hormone problems; be skeptical of "balancing."
Evidence: 🟠 C · Limited
“PCOS makes weight loss impossible.”
Short answer: PCOS makes it harder, not impossible.
What the evidence shows: Insulin resistance in PCOS impedes loss, but lifestyle, metformin and GLP-1s help; even modest loss improves symptoms.
What remains uncertain: Best long-term strategy per phenotype.
Bottom line: Harder but very achievable, and worthwhile.
Evidence: 🟡 B · Promising · PCOS & Weight →
“Estrogen loss at menopause directly makes you gain fat.”
Short answer: Menopause shifts fat toward the abdomen more than it adds large amounts of weight.
What the evidence shows: Total midlife weight gain is driven mainly by ageing and lifestyle; estrogen decline changes fat distribution (more visceral fat).
What remains uncertain: The independent contribution of hormones versus ageing.
Bottom line: Menopause changes where fat goes more than how much.
Evidence: 🟡 B · Promising · Menopause & Weight →
“Low testosterone is why men can't lose weight — just take testosterone.”
Short answer: Obesity lowers testosterone more than the reverse; weight loss often raises it.
What the evidence shows: Visceral fat reduces testosterone; losing weight commonly restores it, while testosterone therapy isn't a weight-loss treatment.
What remains uncertain: Which men benefit from treating genuine hypogonadism alongside weight care.
Bottom line: Treat obesity first; testosterone often follows.
Evidence: 🟡 B · Promising · Men's Health & Obesity →
“A 'hormone panel' should be checked in everyone with obesity.”
Short answer: Reflex broad hormone testing isn't recommended without specific clues.
What the evidence shows: Targeted testing (e.g. TSH, or workup when red flags exist) is appropriate; shotgun panels create false positives and cost without changing management.
What remains uncertain: Which subtle cases merit deeper testing.
Bottom line: Test with a reason, not reflexively.
Evidence: 🟢 A · Established · How Obesity Should Be Evaluated →
9. MASLD / FATTY LIVER
“Fatty liver only happens to people who drink.”
Short answer: Metabolic (non-alcohol) fatty liver — MASLD — is now the most common cause.
What the evidence shows: MASLD is driven by metabolic factors (insulin resistance, obesity, diabetes) and affects many people who drink little or no alcohol.
What remains uncertain: The interaction of moderate alcohol with metabolic risk (MetALD).
Bottom line: You can have serious fatty liver without alcohol.
Evidence: 🟢 A · Established · What Is MASLD? →
“My liver enzymes are normal, so my liver is fine.”
Short answer: Normal ALT/AST does not rule out fatty liver or even fibrosis.
What the evidence shows: Many people with MASLD, and some with advanced fibrosis, have normal enzymes; risk assessment needs more than a liver-enzyme check.
What remains uncertain: The best non-invasive strategy for enzyme-normal patients.
Bottom line: Normal enzymes are reassuring but not a clearance.
Evidence: 🟢 A · Established · "My Liver Tests Are Normal…" →
“Fatty liver is harmless — just a bit of fat.”
Short answer: Simple fat (steatosis) is often benign, but it can progress to inflammation, scarring and cirrhosis.
What the evidence shows: A subset progress from steatosis to MASH to fibrosis; the driver of outcomes is fibrosis, not fat alone.
What remains uncertain: Who will progress and how fast.
Bottom line: Find the fat, then find the risk (fibrosis).
Evidence: 🟢 A · Established · Fatty Liver: The Complete Guide →
“Fat in the liver and scarring of the liver are the same thing.”
Short answer: They're distinct: steatosis (fat) ≠ MASH (inflammation) ≠ fibrosis (scar) ≠ cirrhosis.
What the evidence shows: Imaging fat (CAP/ultrasound/MRI-PDFF) is different from measuring fibrosis (FIB-4, elastography); management hinges on fibrosis.
What remains uncertain: Best combination of tests per patient.
Bottom line: Fat and scar are measured differently and mean different things.
Evidence: 🟢 A · Established · FibroScan & Elastography →
“You need a liver biopsy to know anything.”
Short answer: Most people are risk-stratified without biopsy using blood scores and elastography.
What the evidence shows: FIB-4 and VCTE (FibroScan) reliably rule out most advanced fibrosis; biopsy is reserved for uncertain or discordant cases.
What remains uncertain: Exact thresholds for proceeding to biopsy.
Bottom line: Biopsy is the exception, not the routine first step.
Evidence: 🟢 A · Established · Liver Biopsy: When It's Needed →
“A FIB-4 score is a diagnosis of liver disease.”
Short answer: FIB-4 is a risk estimate, not a diagnosis — it's best at ruling out advanced fibrosis.
What the evidence shows: <1.3 is low risk, 1.3–2.67 indeterminate, >2.67 high; in people ≥65 the lower cutoff is raised (~2.0) to reduce false positives.
What remains uncertain: Indeterminate scores need further testing.
Bottom line: A strong rule-out tool, not a verdict.
Evidence: 🟢 A · Established · FIB-4 Explained →
“Fatty liver is irreversible.”
Short answer: Liver fat, and even some fibrosis, can improve with weight loss and metabolic control.
What the evidence shows: ≥5% weight loss reduces steatosis, ≥7–10% improves MASH, and larger sustained loss (~10%+) can improve fibrosis.
What remains uncertain: How reversible advanced fibrosis and cirrhosis are.
Bottom line: Early disease is often reversible; act before it scars.
Evidence: 🟢 A · Established · Fatty Liver & Weight Loss →
“Only heavy people get fatty liver.”
Short answer: "Lean MASLD" is real, especially with insulin resistance or certain genetics.
What the evidence shows: People with normal BMI can have MASLD, often with central adiposity or genetic predisposition.
What remains uncertain: Optimal screening in lean individuals.
Bottom line: A normal weight doesn't exclude fatty liver.
Evidence: 🟡 B · Promising
There's no medicine for fatty liver, so why bother testing?
Short answer: There are now approved drugs, and identifying risk changes management regardless.
What the evidence shows: Resmetirom (Mar 2024) and semaglutide 2.4 mg (Aug 2025) are approved for noncirrhotic MASH with F2–F3 fibrosis; risk stratification also guides weight, diabetes and cardiovascular care.
What remains uncertain: Long-term outcome data for these drugs are still maturing.
Bottom line: Testing changes management — and treatment now exists.
Evidence: 🟢 A · Established · MASH Medications →
“If I have fatty liver, my liver is what will kill me.”
Short answer: In MASLD, cardiovascular disease is the leading cause of death, not the liver.
What the evidence shows: Most people with MASLD die of cardiovascular disease; the liver matters most in those with advanced fibrosis.
What remains uncertain: Individual risk balance between liver and heart.
Bottom line: Treat the heart risk as seriously as the liver.
Evidence: 🟢 A · Established · MASLD & Cardiovascular Risk →
10. SURGERY
“Bariatric surgery is cheating / the easy way out.”
Short answer: Surgery is a major, effective medical treatment — not a shortcut.
What the evidence shows: It produces large sustained weight loss (~25–30% total is common) and strong metabolic benefits, requiring lifelong follow-up and behaviour change.
What remains uncertain: Best candidate selection versus medication.
Bottom line: A serious, evidence-based treatment for a serious disease.
Evidence: 🟢 A · Established · Bariatric Surgery →
“Surgery is far too dangerous to consider.”
Short answer: Modern bariatric surgery has a strong safety profile relative to its benefits.
What the evidence shows: Perioperative risk is low at experienced centres, and cohort data show reduced long-term mortality; risks include nutritional deficiencies needing lifelong monitoring.
What remains uncertain: Long-term risks vary by procedure and patient.
Bottom line: Real risks, but generally favourable benefit-to-risk.
Evidence: 🟢 A · Established
“Surgery cures diabetes permanently.”
Short answer: It drives high remission rates, especially gastric bypass, but remission isn't always permanent.
What the evidence shows: Many achieve diabetes remission after surgery (notably RYGB); some relapse over years, though benefits often persist.
What remains uncertain: Who maintains remission long-term.
Bottom line: Powerful for diabetes, but "remission" can wane.
Evidence: 🟢 A · Established
“You'll just regain everything after surgery.”
Short answer: Some regain is common, but most keep off a large fraction long-term.
What the evidence shows: Weight typically stabilises above the nadir; substantial durable loss is the norm compared with lifestyle alone.
What remains uncertain: Predictors of significant regain.
Bottom line: Expect some regain, not total reversal.
Evidence: 🟢 A · Established
“Now that we have GLP-1s, surgery is obsolete.”
Short answer: Surgery still produces greater average loss than current drugs and suits many patients.
What the evidence shows: Bariatric surgery generally yields larger sustained loss than medication; the choice depends on goals, comorbidities and preference.
What remains uncertain: How next-generation drugs will compare over decades.
Bottom line: Complementary options, not one replacing the other.
Evidence: 🟡 B · Promising
“Surgery just shrinks your stomach so you eat less.”
Short answer: It also changes gut hormones and appetite biology.
What the evidence shows: Procedures alter GLP-1 and other gut-hormone signalling, which helps explain appetite reduction and metabolic benefits beyond restriction.
What remains uncertain: The exact hormonal mechanisms per procedure.
Bottom line: It's a metabolic operation, not just a smaller stomach.
Evidence: 🟢 A · Established
“After surgery you can eat normally and take no supplements.”
Short answer: Lifelong vitamin/mineral supplementation and monitoring are required.
What the evidence shows: Altered absorption risks deficiencies (iron, B12, calcium, vitamin D); adherence to supplements and follow-up is essential.
What remains uncertain: Individual needs vary by procedure.
Bottom line: Lifelong nutritional care is part of the deal.
Evidence: 🟢 A · Established
“Endoscopic procedures are the same as bariatric surgery.”
Short answer: Endoscopic options are less invasive and generally less effective than surgery.
What the evidence shows: Procedures like endoscopic sleeve or balloons offer moderate loss with lower risk; they suit specific patients but underperform surgery on average.
What remains uncertain: Long-term durability of endoscopic results.
Bottom line: A middle option — less risk, less effect.
Evidence: 🟡 B · Promising · Endoscopic Obesity Treatment →
“Surgery is only about looking better.”
Short answer: Its primary justification is health: diabetes, cardiovascular risk, liver disease, sleep apnea and mortality.
What the evidence shows: Metabolic and mortality benefits, not appearance, drive the indication.
What remains uncertain: Quality-of-life gains vary.
Bottom line: A health treatment, measured by outcomes not looks.
Evidence: 🟢 A · Established
11. MENTAL HEALTH
“If you just had more willpower, you'd lose weight.”
Short answer: Willpower exists but is overwhelmed by biology and environment in obesity.
What the evidence shows: Appetite hormones, reward pathways and the food environment shape eating far beyond conscious control; shaming worsens outcomes.
What remains uncertain: How much behaviour is modifiable in a given person.
Bottom line: Obesity isn't a willpower deficit.
Evidence: 🟢 A · Established · Mental Health & Obesity →
“Emotional eating means you're weak.”
Short answer: Using food to regulate emotion is common and treatable, not a weakness.
What the evidence shows: Stress and emotion drive eating through real neurobiology; behavioural therapy helps.
What remains uncertain: Best therapy match per person.
Bottom line: A treatable pattern, not a character flaw.
Evidence: 🟡 B · Promising
“Binge-eating disorder is just overeating.”
Short answer: It's a recognised psychiatric condition with specific treatments.
What the evidence shows: BED responds to structured psychotherapy and certain medications; it needs diagnosis, not moralising.
What remains uncertain: Interaction with weight-loss treatment.
Bottom line: A real disorder that deserves real treatment.
Evidence: 🟢 A · Established
“Antidepressants always cause big weight gain.”
Short answer: Effects vary widely by drug; some are weight-neutral or reducing.
What the evidence shows: Certain agents promote gain, others don't; the balance of treating depression usually favours mental health.
What remains uncertain: Individual responses differ.
Bottom line: Weight effects are drug-specific — discuss options, don't avoid treatment.
Evidence: 🟡 B · Promising
“Losing weight will fix depression and self-esteem.”
Short answer: Weight loss can help some symptoms but isn't a cure for mental illness.
What the evidence shows: Improvements in mobility and health may lift mood; depression often needs its own treatment.
What remains uncertain: Who experiences mood benefit from weight loss.
Bottom line: Address mental health directly, not only through the scale.
Evidence: 🟡 B · Promising
“Talking about weight bluntly motivates patients.”
Short answer: Weight stigma harms health and undermines care.
What the evidence shows: Shame is associated with worse eating, avoidance of care and poorer outcomes; compassionate framing works better.
What remains uncertain: Best communication strategies per patient.
Bottom line: Respect motivates; shame backfires.
Evidence: 🟢 A · Established
“Food addiction isn't a real thing.”
Short answer: "Food addiction" is debated, but hyper-palatable foods do engage reward circuits.
What the evidence shows: Some eating patterns share features with addiction; the diagnostic label remains contested.
What remains uncertain: Whether it meets formal addiction criteria.
Bottom line: The biology is real; the label is still debated.
Evidence: 🟠 C · Limited
“GLP-1s take away all pleasure from eating and life.”
Short answer: They reduce "food noise" and cravings; broad anhedonia isn't the expected effect.
What the evidence shows: Many patients report quieter food preoccupation and normal enjoyment of meals; report persistent low mood to your clinician.
What remains uncertain: Individual psychological responses vary.
Bottom line: Less craving, not less joy — but monitor mood.
Evidence: 🟡 B · Promising · Food Noise →
“Sleep has nothing to do with weight.”
Short answer: Poor sleep worsens appetite regulation and weight.
What the evidence shows: Short or disrupted sleep raises hunger hormones and cravings and is linked to weight gain; sleep apnea is closely tied to obesity.
What remains uncertain: How much sleep improvement changes weight.
Bottom line: Sleep is a genuine metabolic lever.
Evidence: 🟡 B · Promising
12. GENETICS
“There are no 'obesity genes' — it's all lifestyle.”
Short answer: Genetics strongly influence body weight.
What the evidence shows: Heritability of obesity is roughly 40–70%; hundreds of common variants plus rare monogenic forms contribute.
What remains uncertain: How genes and environment interact for each person.
Bottom line: Genes load the gun; environment pulls the trigger.
Evidence: 🟢 A · Established · Genetics of Obesity →
“If it's genetic, nothing I do matters.”
Short answer: Genetic risk raises susceptibility but doesn't fix your weight.
What the evidence shows: Lifestyle, medication and surgery all work even in genetically predisposed people; genes shift the odds, not the outcome.
What remains uncertain: How much each lever helps a given genotype.
Bottom line: Genetic risk is not genetic destiny.
Evidence: 🟢 A · Established
“One 'fat gene' causes obesity.”
Short answer: Common obesity is polygenic — many genes each with small effects.
What the evidence shows: No single common variant explains much; risk accumulates across many loci.
What remains uncertain: How to combine variants into useful clinical prediction.
Bottom line: It's hundreds of small effects, not one gene.
Evidence: 🟢 A · Established
“Rare genetic obesity can't be treated.”
Short answer: Some monogenic forms have targeted treatment.
What the evidence shows: Setmelanotide is approved for specific rare genetic obesity (e.g. POMC, LEPR, Bardet-Biedl); MC4R pathway defects are the most common monogenic cause.
What remains uncertain: Treatments for many rare variants are still lacking.
Bottom line: Some rare forms are now specifically treatable.
Evidence: 🟢 A · Established
“A commercial DNA test can tell me the perfect diet for my genes.”
Short answer: Direct-to-consumer "nutrigenomic" diet matching isn't validated.
What the evidence shows: Trials don't show that gene-based diet assignment beats standard advice for weight loss.
What remains uncertain: Precision-nutrition research is ongoing but not yet clinical.
Bottom line: Skip the "genetic diet" — it's not proven.
Evidence: 🔴 D · Experimental
“Obesity genes skip a generation / aren't inherited.”
Short answer: Weight strongly clusters in families through shared genes and environment.
What the evidence shows: Family and twin studies confirm high heritability alongside shared lifestyle.
What remains uncertain: Disentangling genes from environment precisely.
Bottom line: It runs in families — genetically and environmentally.
Evidence: 🟢 A · Established
“Epigenetics means my parents' habits doomed me.”
Short answer: Developmental and epigenetic factors influence risk but aren't a fixed sentence.
What the evidence shows: Early-life environment affects later metabolic risk; these influences are modifiable, not deterministic.
What remains uncertain: How reversible specific epigenetic effects are.
Bottom line: An influence on risk, not a locked fate.
Evidence: 🟠 C · Limited
“Since obesity is genetic, medication is unnecessary — or the only answer.”
Short answer: Genetics support using effective tools, including medication, not avoiding or over-relying on them.
What the evidence shows: Genetic predisposition is exactly why many need pharmacologic help alongside lifestyle.
What remains uncertain: Matching treatment to genetic subtype is still experimental.
Bottom line: Genes justify treatment; they don't dictate one single tool.
Evidence: 🟡 B · Promising
“Your body type (ectomorph/endomorph) determines everything.”
Short answer: "Somatotypes" are a loose descriptive idea, not a precise biological law.
What the evidence shows: Body shape has genetic input, but "types" don't reliably predict response to diet or training.
What remains uncertain: Better individual predictors are being studied.
Bottom line: A rough description, not a fixed destiny.
Evidence: 🟠 C · Limited
13. AGING
“Weight gain with age is inevitable and unstoppable.”
Short answer: It's common but largely driven by modifiable factors.
What the evidence shows: Falling activity, muscle loss and lifestyle — not an inevitable metabolic collapse — drive most age-related gain, and total expenditure is stable through midlife.
What remains uncertain: How much hormonal change contributes in later decades.
Bottom line: Common, but not fixed by biology alone.
Evidence: 🟡 B · Promising
“Older adults shouldn't try to lose weight.”
Short answer: Weight loss can help older adults, but must protect muscle and bone.
What the evidence shows: Loss improves function and metabolic health in older people when combined with resistance training and adequate protein to limit muscle and bone loss.
What remains uncertain: Optimal targets in the very old or frail.
Bottom line: Yes, carefully — with muscle preservation front and centre.
Evidence: 🟡 B · Promising
“Sarcopenia (muscle loss) is just normal aging you can't fight.”
Short answer: Age-related muscle loss is real but substantially preventable.
What the evidence shows: Resistance training and protein blunt sarcopenia at any age; inactivity accelerates it.
What remains uncertain: Ideal dose across ages and health states.
Bottom line: You can fight muscle loss — mostly by lifting and eating protein.
Evidence: 🟢 A · Established
“A little extra weight is protective in older age, so ignore it.”
Short answer: The "obesity paradox" is partly a statistical artifact; excess fat still carries risk.
What the evidence shows: Some cohorts show lower mortality at modestly higher BMI in old age, confounded by illness-related weight loss and muscle mass; fitness and body composition matter more than BMI.
What remains uncertain: The true protective range, if any, in the elderly.
Bottom line: Don't over-read the paradox; focus on function and fitness.
Evidence: 🟠 C · Limited
“GLP-1s are unsafe in older adults.”
Short answer: They can be used in older adults with attention to muscle, nutrition and hydration.
What the evidence shows: Trials included older participants; the main cautions are protecting lean mass and avoiding excess loss of appetite/intake.
What remains uncertain: Long-term outcomes specifically in the elderly.
Bottom line: Usable with extra attention to muscle and nutrition.
Evidence: 🟡 B · Promising
“It's too late to benefit from losing weight or exercising.”
Short answer: Benefits accrue at any age.
What the evidence shows: Older adults gain function, metabolic health and mortality benefit from activity and appropriate weight management.
What remains uncertain: Magnitude varies by baseline health.
Bottom line: Never too late to benefit.
Evidence: 🟢 A · Established
“Metabolism nose-dives every decade after 30.”
Short answer: Adjusted metabolic rate holds steady from ~20 to ~60, then declines slowly.
What the evidence shows: Large expenditure datasets show stability through midlife, not steady decade-by-decade collapse.
What remains uncertain: Individual variation around the average curve.
Bottom line: No per-decade metabolic cliff before 60.
Evidence: 🟡 B · Promising
“Older adults don't need much protein.”
Short answer: Older adults often need more protein, not less, to preserve muscle.
What the evidence shows: Anabolic resistance with age means higher protein intake helps maintain muscle, especially with resistance training.
What remains uncertain: Exact optimal targets by health status.
Bottom line: Prioritise protein to protect ageing muscle.
Evidence: 🟡 B · Promising
“Belly fat in older age is just cosmetic.”
Short answer: Visceral fat is metabolically active and raises cardiometabolic risk at any age.
What the evidence shows: Central adiposity is linked to diabetes, cardiovascular disease and fatty liver independent of overall weight.
What remains uncertain: Best individual measure and target.
Bottom line: Visceral fat is a health issue, not just appearance.
Evidence: 🟢 A · Established
14. MENOPAUSE
“Menopause makes weight loss impossible.”
Short answer: It's harder, not impossible.
What the evidence shows: Muscle loss, activity decline and fat redistribution complicate loss, but diet, resistance training and medication still work.
What remains uncertain: Best strategy per individual.
Bottom line: Harder and very achievable.
Evidence: 🟡 B · Promising · Menopause & Weight →
“Menopause causes large weight gain by itself.”
Short answer: The menopause transition mainly redistributes fat; total gain is largely ageing and lifestyle.
What the evidence shows: Estrogen decline increases visceral (abdominal) fat, while overall midlife gain tracks with ageing and behaviour.
What remains uncertain: The independent hormonal contribution to total weight.
Bottom line: More about fat location than sheer weight gain.
Evidence: 🟡 B · Promising
“Hormone therapy is a weight-loss treatment.”
Short answer: HRT isn't prescribed for weight loss, though it may modestly limit abdominal fat gain.
What the evidence shows: Menopausal hormone therapy can influence fat distribution somewhat; it isn't an obesity treatment.
What remains uncertain: Long-term body-composition effects.
Bottom line: HRT treats menopausal symptoms, not obesity.
Evidence: 🟠 C · Limited
“'Menopause belly' can't be changed.”
Short answer: Visceral fat responds to weight loss, exercise and strength training.
What the evidence shows: Diet plus resistance and aerobic training reduce visceral fat, including after menopause.
What remains uncertain: How much redistribution can be fully reversed.
Bottom line: It's modifiable with the right approach.
Evidence: 🟡 B · Promising
“GLP-1s don't work as well in menopausal women.”
Short answer: GLP-1 medications are effective across sexes and menopausal status.
What the evidence shows: Trials show strong effects in women; menopause doesn't negate efficacy.
What remains uncertain: Subgroup differences are not well characterised.
Bottom line: They work in menopausal women too.
Evidence: 🟡 B · Promising
“Weight gain at menopause is just water retention.”
Short answer: Changes are mainly fat redistribution and some muscle loss, not simply fluid.
What the evidence shows: Body-composition studies show increased visceral fat and decreased lean mass over the transition.
What remains uncertain: Short-term fluid shifts also occur.
Bottom line: It's real body-composition change, not just water.
Evidence: 🟡 B · Promising
“You should stop strength training at menopause.”
Short answer: The opposite — strength training becomes more important.
What the evidence shows: Resistance training protects muscle and bone, counters visceral fat, and supports metabolism during and after menopause.
What remains uncertain: Optimal program varies.
Bottom line: Lift more, not less, at menopause.
Evidence: 🟢 A · Established
“Perimenopause is too early to address weight and metabolic risk.”
Short answer: Perimenopause is an ideal window to build habits and assess risk.
What the evidence shows: Metabolic changes begin before the final period; early action on muscle, activity and diet pays off.
What remains uncertain: Best timing of specific interventions.
Bottom line: Start in perimenopause, not after.
Evidence: 🟡 B · Promising
“Menopausal weight change means your thyroid is failing.”
Short answer: Thyroid disease is worth checking but rarely the main driver.
What the evidence shows: Thyroid problems become more common with age but usually explain only modest weight change; menopause and lifestyle dominate.
What remains uncertain: Overlapping symptoms complicate attribution.
Bottom line: Check the thyroid, but don't assume it's the cause.
Evidence: 🟡 B · Promising
15. MEN'S HEALTH
“Men lose weight effortlessly compared with women.”
Short answer: Men often lose faster early on, but keeping it off is hard for everyone.
What the evidence shows: Greater muscle mass can speed early loss in men, yet long-term maintenance challenges apply across sexes.
What remains uncertain: Sex differences in long-term outcomes.
Bottom line: A head start, not an easy ride.
Evidence: 🟡 B · Promising · Men's Health & Obesity →
“Testosterone therapy is a good weight-loss treatment for men.”
Short answer: Testosterone isn't a weight-loss drug; treat obesity first.
What the evidence shows: Obesity lowers testosterone, and weight loss often raises it; testosterone therapy is for diagnosed hypogonadism, not obesity.
What remains uncertain: Who benefits from combined care.
Bottom line: Lose weight to help testosterone, not the reverse.
Evidence: 🟡 B · Promising
“Belly fat in men is harmless 'dad bod.'”
Short answer: Central (visceral) fat is the most metabolically dangerous kind.
What the evidence shows: Abdominal obesity strongly predicts diabetes, cardiovascular disease and fatty liver in men.
What remains uncertain: Best individual risk measure.
Bottom line: Visceral belly fat is a real health risk.
Evidence: 🟢 A · Established
“Erectile dysfunction has nothing to do with weight.”
Short answer: Obesity and metabolic disease are common, reversible contributors to ED.
What the evidence shows: Vascular dysfunction and low testosterone link obesity to ED; weight loss can improve it.
What remains uncertain: Degree of improvement per individual.
Bottom line: Weight and vascular health matter for ED.
Evidence: 🟡 B · Promising
“Men don't get eating disorders or emotional eating.”
Short answer: They do — often underdiagnosed.
What the evidence shows: Binge eating and disordered eating occur in men and are frequently missed.
What remains uncertain: True prevalence due to under-reporting.
Bottom line: Men experience these too; screen without bias.
Evidence: 🟡 B · Promising
“Sleep apnea is just snoring, unrelated to weight.”
Short answer: Obesity is a major driver of obstructive sleep apnea, which harms metabolic health.
What the evidence shows: Weight loss improves OSA; tirzepatide is approved for moderate-to-severe OSA in adults with obesity.
What remains uncertain: Long-term OSA outcomes with weight-based treatment.
Bottom line: OSA is weight-linked and treatable.
Evidence: 🟢 A · Established
“Muscle-building means you can ignore fat and diet.”
Short answer: Muscle helps, but visceral fat and diet still determine metabolic health.
What the evidence shows: You can be muscular and metabolically unhealthy; body composition and diet quality both matter.
What remains uncertain: Individual thresholds.
Bottom line: Build muscle and manage fat and diet.
Evidence: 🟡 B · Promising
“GLP-1s will ruin a man's gym gains.”
Short answer: With protein and resistance training, strength and muscle can be protected during loss.
What the evidence shows: Some lean-mass loss accompanies any weight loss; training and protein preserve function.
What remains uncertain: Long-term strength outcomes need more data.
Bottom line: Protect gains with lifting and protein.
Evidence: 🟡 B · Promising · GLP-1 & Muscle Loss →
“Men don't need to worry about osteoporosis during weight loss.”
Short answer: Rapid loss can affect bone in men too.
What the evidence shows: Weight loss can reduce bone density; resistance training, protein and adequate vitamin D/calcium help protect it.
What remains uncertain: Magnitude of male bone risk during loss.
Bottom line: Protect bone as well as muscle.
Evidence: 🟡 B · Promising
16. PEDIATRICS
“Kids will just grow out of obesity.”
Short answer: Most children with obesity do not simply outgrow it.
What the evidence shows: Childhood obesity often tracks into adulthood; early support improves trajectories.
What remains uncertain: Who spontaneously improves.
Bottom line: Don't wait for them to grow out of it.
Evidence: 🟢 A · Established · Pediatric & Adolescent Obesity →
“Putting a child on any 'diet' is the right fix.”
Short answer: Restrictive dieting can harm children; family-based healthy-habit approaches are preferred.
What the evidence shows: Guidelines favour family lifestyle interventions and, when indicated, structured programs — not fad restriction.
What remains uncertain: Best intensity for each family.
Bottom line: Support healthy habits, avoid harmful restriction.
Evidence: 🟢 A · Established
“Childhood obesity is only about diet and exercise.”
Short answer: Genetics, environment, sleep, stress and socioeconomics all contribute.
What the evidence shows: Multiple factors drive pediatric obesity; blaming the child or parents oversimplifies.
What remains uncertain: Relative weight of each factor per child.
Bottom line: It's multifactorial, like adult obesity.
Evidence: 🟢 A · Established
“Obesity medications should never be used in adolescents.”
Short answer: Some GLP-1 medications are approved for adolescents with obesity.
What the evidence shows: Trials support certain agents in adolescents alongside lifestyle; use is individualized and specialist-guided. [verify specific agent approvals]
What remains uncertain: Long-term effects during growth.
Bottom line: A considered option for some adolescents, not a blanket ban.
Evidence: 🟡 B · Promising
“Bariatric surgery is never appropriate for teens.”
Short answer: For severe adolescent obesity, surgery can be appropriate at experienced centres.
What the evidence shows: Guidelines support metabolic surgery for select adolescents with severe obesity and comorbidities.
What remains uncertain: Very-long-term outcomes into adulthood.
Bottom line: A carefully selected option, not categorically off-limits.
Evidence: 🟡 B · Promising
“BMI charts don't apply to children.”
Short answer: Children use age- and sex-specific BMI percentiles, which are useful screens.
What the evidence shows: Pediatric BMI percentiles help identify risk; like adults, they're a starting point, not the whole story.
What remains uncertain: Best complementary measures in kids.
Bottom line: Use pediatric percentiles as a screen.
Evidence: 🟢 A · Established
“Talking to kids about weight causes eating disorders.”
Short answer: Weight-focused shaming can harm; supportive, health-focused conversations do not.
What the evidence shows: Non-stigmatising, family-based communication is safe and helpful; teasing and dieting pressure raise disorder risk.
What remains uncertain: Best messaging by age.
Bottom line: How you talk matters more than whether you talk.
Evidence: 🟡 B · Promising
“Fatty liver doesn't happen in children.”
Short answer: Pediatric MASLD is increasingly common with childhood obesity.
What the evidence shows: Children can develop metabolic fatty liver and even fibrosis; screening is recommended in higher-risk kids.
What remains uncertain: Optimal pediatric screening thresholds.
Bottom line: Children get fatty liver too — screen when at risk.
Evidence: 🟡 B · Promising
“Sugary-drink limits don't matter for kids' weight.”
Short answer: Sugar-sweetened beverages are among the clearest dietary drivers of pediatric weight gain.
What the evidence shows: Reducing sugary drinks is consistently linked to better weight outcomes in children.
What remains uncertain: Effect size varies by overall diet.
Bottom line: Cutting sugary drinks is a high-yield step.
Evidence: 🟢 A · Established
17. WEIGHT MAINTENANCE
“Regaining weight means you failed.”
Short answer: Regain is a biological feature of obesity, not a moral failure.
What the evidence shows: After loss, hunger rises and expenditure falls, defending the old weight; regain reflects physiology, and maintenance often needs ongoing treatment.
What remains uncertain: Who can maintain without pharmacotherapy.
Bottom line: Regain is expected biology — plan for it, don't blame yourself.
Evidence: 🟢 A · Established · Weight Regain & Maintenance →
“Once you hit your goal weight, you can stop everything.”
Short answer: Maintenance is an active, ongoing phase, not a finish line.
What the evidence shows: Sustained behaviours (activity, monitoring, protein) and often continued medication are needed to prevent regain.
What remains uncertain: Minimum "dose" of effort or drug to maintain.
Bottom line: Maintenance is a continuing treatment, not a stopping point.
Evidence: 🟢 A · Established
“If you stop the medication, you should easily keep the weight off.”
Short answer: Stopping effective medication usually causes regain.
What the evidence shows: After semaglutide, roughly two-thirds of lost weight returns within about a year; other GLP-1s show regain on withdrawal.
What remains uncertain: Whether structured support limits regain for some.
Bottom line: Discontinuation generally means regain.
Evidence: 🟢 A · Established
“Exercise doesn't help once you've lost the weight.”
Short answer: Physical activity is one of the strongest predictors of successful maintenance.
What the evidence shows: People who keep weight off tend to be consistently active; exercise protects muscle and metabolic health.
What remains uncertain: Optimal type and volume per person.
Bottom line: For maintenance, exercise is essential.
Evidence: 🟢 A · Established · Exercise, Muscle & Body Composition →
“Weighing yourself often is unhealthy obsession.”
Short answer: For many, regular self-monitoring supports maintenance without harm.
What the evidence shows: Consistent self-weighing is associated with better weight control; it should be framed as data, not judgement, and adjusted for anyone with disordered eating.
What remains uncertain: Best frequency for each person.
Bottom line: Monitoring helps most people maintain — as information, not a verdict.
Evidence: 🟡 B · Promising
“A maintenance dose of GLP-1 keeps working forever with no effort.”
Short answer: Medication helps maintain, but nutrition, activity and muscle still matter.
What the evidence shows: Continued treatment sustains much of the loss; combining it with healthy behaviour gives the best body composition and health.
What remains uncertain: Long-term maintenance-dose strategies are still being defined.
Bottom line: Medication plus habits, not medication alone.
Evidence: 🟡 B · Promising
“Slow, small weight loss can't produce real health benefits.”
Short answer: Even modest sustained loss yields meaningful health gains.
What the evidence shows: ~5–10% loss improves glucose, blood pressure, lipids and liver fat; sustaining it matters more than speed.
What remains uncertain: Individual variation in benefit.
Bottom line: Modest, lasting loss is genuinely valuable.
Evidence: 🟢 A · Established
“Maintenance is about the scale number and nothing else.”
Short answer: Health markers — waist, labs, fitness, strength, liver — matter more than a single number.
What the evidence shows: Body composition and metabolic health predict outcomes better than weight alone.
What remains uncertain: Best composite target per person.
Bottom line: Track health, not just the scale.
Evidence: 🟢 A · Established · BMI, Body Fat & Body Composition →
Questions patients ask
What's the single most common myth you hear?
That obesity is simply a willpower problem. It isn't — body weight is regulated by genetics, hormones, medications, sleep and environment, and treating it medically is not "cheating." Grade A 🟢 → Obesity as a Chronic Disease (/understand/chronic-disease)
Is my metabolism really "broken"?
Not broken — adapted. Weight loss lowers energy expenditure somewhat and increases hunger, which defends your old weight and explains regain. That's physiology, not damage. Grade B 🟡 → Weight Regain (/understand/weight-regain)
Are GLP-1 medications a quick fix I take for a few months?
No. Obesity is chronic, and stopping usually leads to regain — after semaglutide, roughly two-thirds of lost weight returns within about a year. They're generally long-term treatments. Grade A 🟢 → GLP-1 hub (/treat/glp1)
Does berberine really work like Ozempic?
No. Berberine modestly affects glucose and lipids but is not a GLP-1 and has limited, inconsistent weight-loss evidence. "Nature's Ozempic" is marketing. Grade C 🟠 → Weight-Loss Supplements (/treat/supplements)
My liver enzymes are normal — can I stop worrying about fatty liver?
Not entirely. Normal ALT/AST doesn't rule out fatty liver or even fibrosis; risk is assessed with tools like FIB-4 and elastography. Grade A 🟢 → "My Liver Tests Are Normal…" (/fatty-liver/normal-enzymes)
If I regain weight, did I fail?
No. Regain is a biological response to weight loss, not a moral failure — which is exactly why maintenance often needs ongoing treatment. Grade A 🟢 → Weight Regain & Maintenance (/understand/weight-regain)
Is bariatric surgery the "easy way out"?
No. It's a major, effective medical treatment producing large sustained loss and metabolic benefit, with lifelong follow-up. Grade A 🟢 → Bariatric Surgery (/treat/bariatric-surgery)
KEEP READING
- 25 Things You Probably Believe About Weight Loss That Aren't Quite True — the flagship deep-dive on the biggest half-truths. (
/myths/25-things) - Why Weight Is So Hard to Lose — the biology behind most metabolism myths. (
/understand/why-weight-is-hard) - GLP-1 & Incretin Medications — the evidence behind the GLP-1, semaglutide and tirzepatide entries. (
/treat/glp1) - Fatty Liver: The Complete Guide — the MASLD myths in full depth. (
/fatty-liver) - Weight-Loss Supplements — every supplement claim, graded. (
/treat/supplements)
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: STEP 1/2/4 and SELECT (semaglutide); SURMOUNT-1/4/5 and SURMOUNT-OSA (tirzepatide); ESSENCE and resmetirom labeling (MASH); FDA approvals of oral semaglutide 25 mg (Dec 2025), semaglutide for MASH (Aug 2025), tirzepatide for OSA (Dec 2024); setmelanotide labeling; bariatric-surgery cohort data; general obesity, endocrine, hepatology and nutrition guidelines. Evidence grades reflect strength of evidence about each claim, not endorsement. Educational only; not individualized advice.
